U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C24H24ClNO3
Molecular Weight 409.905
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ENICLOBRATE

SMILES

CCC(C)(OC1=CC=C(CC2=CC=C(Cl)C=C2)C=C1)C(=O)OCC3=CN=CC=C3

InChI

InChIKey=VKNSAVOURPMBRN-UHFFFAOYSA-N
InChI=1S/C24H24ClNO3/c1-3-24(2,23(27)28-17-20-5-4-14-26-16-20)29-22-12-8-19(9-13-22)15-18-6-10-21(25)11-7-18/h4-14,16H,3,15,17H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C24H24ClNO3
Molecular Weight 409.905
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Eniclobrate (Sgd 33374), a diphenylmethane derivative, is a lipid-lowering compound. In rodents, eniclobrate lower serum and liver cholesterol levels and reduced the percentage of esterified cholesterol present in the serum but raised liver triglyceride levels. In a clinical trial for the treatment of hyperlipidemia type IIa and type IIb eniclobrate effectively reduced LDL-cholesterol in type IIa, however, there was a remarkable increase in HDL-cholesterol in both types of hyperlipidemia.

Originator

Approval Year

PubMed

Substance Class Chemical
Record UNII
M469UFX48N
Record Status Validated (UNII)
Record Version